NLSP

Funding Approval: The Israel-U.S. Binational Industrial Research and Development Foundation has approved a milestone-based funding payment to Kadimastem Ltd. for their collaboration with iTolerance, Inc. on the development of iTOL-102, a potential cure for Type 1 diabetes.

Significant Progress: The funding is based on the significant advancements made by Kadimastem and iTolerance in co-developing iTOL-102, which aims to provide a treatment option that eliminates the need for lifelong immunosuppression drugs.

Greenbrier Companies Earnings Surge: The Greenbrier Companies, Inc. reported quarterly earnings of $1.86 per share, significantly exceeding market expectations of 98 cents, leading to a 13.1% increase in their stock price during pre-market trading.

Pre-Market Stock Movements: Various stocks experienced notable fluctuations in pre-market trading, with CID HoldCo, Inc. and Namib Minerals seeing substantial gains of over 150%, while BioNexus Gene Lab Corp. and Centene Corporation faced significant declines of over 25%.

Equity Financing Completion: NLS Pharmaceutics has successfully completed a $3 million equity financing, including a final closing of $1 million, to support its merger with Kadimastem and fund working capital for developing therapies for CNS disorders.

Investor Confidence and Future Plans: The completion of this financing round reflects strong investor confidence in both companies' strategic vision, enabling them to advance clinical trials for treatments targeting ALS and diabetes.